Kilitch Drugs India Ltd

Kilitch Drugs India Ltd

$KILITCHPharmaceuticalsNSEBSE

Kilitch Drugs India Ltd (KILITCH) last traded at ₹173, a market capitalisation of ₹605 crore, on a P/E of 20.1. Over the past 52 weeks the stock has ranged between ₹117 and ₹220. Kilitch Drugs India Ltd last reported results for the quarter ended Jun 2026, with sales of ₹44.88 crore and net profit of ₹1.96 crore. Kilitch Drugs India Ltd’s annual general meeting is scheduled for 27 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.

Kilitch Drugs India Ltd share price and key metrics

Current price
₹173
Market cap
₹605 cr
Stock P/E
20.1
Book value
₹80
ROE
10.6%
ROCE
13.4%
Dividend yield
0.00%
52w high / low
220/117

Metrics as of 25 Aug 2026. Not real time.

Kilitch Drugs India Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹44.88 cr, up 4.0% from ₹43.14 cr a year earlier. Net profit was ₹1.96 cr, down 13.7% year on year.

Kilitch Drugs India Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales47.4756.1761.2343.1448.9253.8189.644.88
Expenses41.3747.4446.6439.8843.8847.6667.4641.94
Operating profit6.18.7314.593.265.046.1522.142.94
OPM %12.85%15.54%23.83%7.56%10.30%11.43%24.71%6.55%
Other income5.161.731.72.566.661.530.492.9
Interest0.311.41.61.531.441.151.440.88
Depreciation0.610.810.850.840.860.940.981.09
Profit before tax10.348.2513.843.459.45.5920.213.87
Tax %16.73%32.00%26.23%34.49%14.47%22.90%26.37%48.84%
Net profit8.615.6110.222.278.044.3114.881.96
EPS (₹)2.461.702.970.872.341.274.150.83

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Kilitch Drugs India Ltd annual results

Kilitch Drugs India Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales68114140154198235237
Operating profit5101824323736
OPM %8%9%13%16%16%16%15%
Net profit46814253029
EPS (₹)1.092.173.084.177.638.638.59

TTM is the trailing twelve months to the most recent quarter.

Kilitch Drugs India Ltd growth and returns

Compounded Sales Growth
10 Years
27%
5 Years
28%
3 Years
19%
TTM
14%
Compounded Profit Growth
10 Years
16%
5 Years
55%
3 Years
38%
TTM
7%
Stock Price CAGR
10 Years
26%
5 Years
16%
3 Years
22%
1 Year
-14%
Return on Equity
10 Years
5%
5 Years
9%
3 Years
10%
Last Year
11%

Kilitch Drugs India Ltd shareholding pattern

Promoters held 63.77% at Jun 2026, down from 69.23% at Jun 2025. FIIs 0.12%.

Kilitch Drugs India Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters69.23%69.23%69.23%69.23%63.77%63.77%63.77%63.77%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.12%
Public30.77%30.76%30.77%30.77%36.22%36.23%36.22%36.11%
No. of shareholders9,92010,1399,74910,37910,92912,04311,78512,627

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is Kilitch Drugs India Ltd’s AGM?

Kilitch Drugs India Ltd’s annual general meeting is scheduled for 27 Aug 2026.

  • AGM34th Annual General Meeting to transact business and review Annual Report for FY2025-26

See the full results calendar for every Indian company reporting in the next 30 days.

Kilitch Drugs India Ltd corporate filings

  • We are submitting herewith the monitoring agency reportCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Kilitch Drugs India Ltd has submitted its Monitoring Agency Report as per Regulation 30…

    Read the full analysis
  • We are submitting herewith the publication of extract of the financial results for the quarter ended 30th June 2026Company Updatemedium impact
    Filing PDF

    Cruxal's analysis: Kilitch Drugs (India) Ltd. has released its financial results for the quarter ended 30th…

    Read the full analysis
  • We are submitting herewith the financial results for the quarter ended 30th June 2026Resulthigh impact
    Filing PDF

    Cruxal's analysis: Kilitch Drugs (India) Ltd. reported a weak performance for the quarter ended 30th June…

    Read the full analysis
  • Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve unaudited standalone and ....Board Meetinglow impact
    Filing PDF

    Cruxal's analysis: Kilitch Drugs (India) Ltd. has formally intimated the stock exchanges regarding a Board…

    Read the full analysis
  • We are submitting herewith the copy of the newspaper publication of extract of AGM NoticeCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Kilitch Drugs (India) Ltd. has announced the newspaper publication on August 4, 2026…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Kilitch Drugs India Ltd

Cruxal reads every Kilitch Drugs India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Kilitch Drugs India Ltd (KILITCH) Results, Financials & Share Price | Cruxal